Analyst Price Target is $34.60
▲ +271.64% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Marinus Pharmaceuticals in the last 3 months. The average price target is $34.60, with a high forecast of $40.00 and a low forecast of $23.00. The average price target represents a 271.64% upside from the last price of $9.31.
Current Consensus is
The current consensus among 7 investment analysts is to buy stock in Marinus Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.